The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
Positive opinions based on significant survival benefit
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Approval broadens indication for ENHERTU to earlier use in metastatic breast cancer and requirement for confirmatory phase 3 trial
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Subscribe To Our Newsletter & Stay Updated
